HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

S Ugurel Selected Research

Therapeutics

12/2021High tumour mutational burden and EGFR/MAPK pathway activation are therapeutic targets in metastatic porocarcinoma.
11/2021Response durability after cessation of immune checkpoint inhibitors in patients with metastatic Merkel cell carcinoma: a retrospective multicenter DeCOG study.
9/2021[Cutaneous angiosarcoma clinically presenting as Quincke's edema].
11/2020GNAQ and GNA11 mutant nonuveal melanoma: a subtype distinct from both cutaneous and uveal melanoma.
7/2020[Immunotherapy for malignant melanoma].
1/2020Elevated baseline serum PD-1 or PD-L1 predicts poor outcome of PD-1 inhibition therapy in metastatic melanoma.
8/2017Metastatic recurrence of 17-year relapse-free melanoma during anti-TNFa therapy.
9/2015Erythema nodosum-like lesions during BRAF inhibitor therapy: Report on 16 new cases and review of the literature.
3/2015A multicenter DeCOG study on predictors of vemurafenib therapy outcome in melanoma: pretreatment impacts survival.
7/2014[Cutaneous side effects of anti-tumor therapy with BRAF and MEK inhibitors].
For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


S Ugurel Research Topics

Disease

33Melanoma (Melanoma, Malignant)
11/2020 - 09/2000
17Neoplasms (Cancer)
01/2022 - 01/2001
9Neoplasm Metastasis (Metastasis)
12/2021 - 01/2001
3Disease Progression
11/2021 - 08/2000
3Circulating Neoplastic Cells
03/2001 - 01/2001
2Hemangiosarcoma (Angiosarcoma)
09/2021 - 02/2009
2Body Weight (Weight, Body)
01/2001 - 08/2000
1Squamous Cell Carcinoma (Epidermoid Carcinoma)
01/2022
1Hematologic Neoplasms (Hematological Malignancy)
01/2022
1Skin Neoplasms (Skin Cancer)
12/2021
1Eccrine Porocarcinoma
12/2021
1Merkel Cell Carcinoma
11/2021
1Fatigue
11/2021
1Uveal melanoma
11/2020
1Erythema Nodosum
09/2015
1Hemorrhage
07/2011
1Renal Cell Carcinoma (Grawitz Tumor)
07/2011
1Psoriasis (Pustulosis Palmaris et Plantaris)
10/2008
1Brain Neoplasms (Brain Tumor)
10/2006
1Panniculitis
09/2003
1Cutaneous Malignant Melanoma
07/2003
1Hematemesis
06/2003
1Dyspepsia (Indigestion)
06/2003
1Hypersensitivity (Allergy)
04/2003
1Lymphatic Metastasis
01/2001

Drug/Important Bio-Agent (IBA)

5Proteins (Proteins, Gene)FDA Link
12/2021 - 09/2001
5ImmunosorbentsIBA
01/2020 - 01/2001
5EnzymesIBA
01/2020 - 01/2001
4Imatinib Mesylate (Gleevec)FDA Link
10/2008 - 04/2003
4Messenger RNA (mRNA)IBA
09/2001 - 01/2001
4Interferon-alpha (Interferon Alfa)IBA
07/2001 - 01/2000
3Immune Checkpoint InhibitorsIBA
01/2022 - 11/2020
3Phosphotransferases (Kinase)IBA
12/2021 - 07/2014
3InterferonsIBA
07/2011 - 07/2001
3Temozolomide (Temodar)FDA LinkGeneric
04/2008 - 09/2000
3Dacarbazine (DIC)FDA LinkGeneric
04/2006 - 04/2001
3Monophenol Monooxygenase (Tyrosinase)IBA
03/2001 - 01/2001
2B7-H1 AntigenIBA
11/2020 - 01/2020
2Biomarkers (Surrogate Marker)IBA
01/2020 - 02/2005
2VemurafenibIBA
09/2015 - 03/2015
2Cisplatin (Platino)FDA LinkGeneric
09/2015 - 09/2000
2Sorafenib (BAY 43-9006)FDA Link
07/2011 - 10/2008
2Imiquimod (Aldara)FDA LinkGeneric
08/2006 - 09/2002
2Interleukin-2 (IL2)IBA
02/2004 - 04/2001
2HLA-G Antigens (HLA G)IBA
04/2002 - 07/2001
2Cytostatic AgentsIBA
07/2001 - 01/2001
2RNA-Directed DNA Polymerase (Reverse Transcriptase)IBA
03/2001 - 01/2001
2Complementary DNA (cDNA)IBA
01/2001 - 01/2001
2MethylprednisoloneFDA LinkGeneric
01/2001 - 08/2000
1Cyclin-Dependent Kinase Inhibitor p16IBA
12/2021
1erucylphosphocholineIBA
12/2021
1Delta CateninIBA
12/2021
12-methylphenyl cinnamateIBA
12/2021
1Programmed Cell Death 1 ReceptorIBA
01/2020
1trametinibIBA
09/2015
1Small Interfering RNA (siRNA)IBA
09/2015
1dabrafenibIBA
09/2015
1Mitogen-Activated Protein Kinase Kinases (MEKs)IBA
07/2014
1Paclitaxel (Taxol)FDA LinkGeneric
02/2009
1Etanercept (Enbrel)FDA Link
10/2008
1Adalimumab (Humira)FDA Link
10/2008
1Infliximab (Remicade)FDA Link
10/2008
1Sunitinib (Sutent)FDA Link
10/2008
1Alefacept (Amevive)FDA Link
10/2008
1efalizumab (Raptiva)FDA Link
10/2008
1peginterferon alfa-2b (Pegintron)FDA Link
04/2008
1beta-apocarotenoid-14',13'-dioxygenase (ADO)IBA
10/2006
1Hyaluronan ReceptorsIBA
05/2006
1Dexamethasone (Maxidex)FDA LinkGeneric
05/2006
1Conditioned Culture MediaIBA
05/2006
1Peptides (Polypeptides)IBA
04/2006
1Platelet-Derived Growth Factor Receptors (Platelet-Derived Growth Factor Receptor)IBA
04/2005
1Tumor Biomarkers (Tumor Markers)IBA
02/2005
1L-Lactate Dehydrogenase (Lactate Dehydrogenase)IBA
02/2005
1liposomal doxorubicin (Doxil)FDA Link
12/2004
1AntigensIBA
07/2003
1Retinaldehyde (Retinal)IBA
07/2003
1EpitopesIBA
07/2003
1RNA (Ribonucleic Acid)IBA
09/2001
1Ribonucleases (Ribonuclease)IBA
09/2001
1Histocompatibility Antigens Class IIBA
07/2001
1HLA Antigens (Human Leukocyte Antigens)IBA
07/2001
1LigandsIBA
05/2001
1Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor)IBA
01/2001
1Interleukin-8 (Interleukin 8)IBA
01/2001
1angiogeninIBA
01/2001
1Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA
01/2001
1Granzymes (Granzyme)IBA
01/2001
1Adrenal Cortex Hormones (Corticosteroids)IBA
01/2001
1Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA
01/2001
1Interleukin-15 (Interleukin 15)IBA
01/2001

Therapy/Procedure

25Therapeutics
12/2021 - 08/2000
7Drug Therapy (Chemotherapy)
09/2021 - 06/2003
5Immunotherapy
01/2022 - 07/2001
1Withholding Treatment
11/2021
1Duration of Therapy
11/2021
1Molecular Targeted Therapy
10/2008
1Oral Administration
10/2006
1Lymph Node Excision (Lymph Node Dissection)
06/2003
1Tonsillectomy
06/2003